MedTrace Logo

EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease

NCT01310309 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2012-12-21

No results posted yet for this study

Summary

The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary Artery Disease (MVD).

Conditions

Interventions

DEVICE

Coronary artery placement of a drug-eluting stent

Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Corrado Vassanelli, MD · Ospedale Civile Maggiore - Università di Verona

  • Flavio Ribichini, MD · Ospedale Civile Maggiore - Università di Verona

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-10-31
Completion
2011-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01310309 on ClinicalTrials.gov